HBM (2142) investor relations material

Executive summary

• Revenue for the six months ended 30 June 2026 was $122.5M, up 20.9% year-over-year, driven by new and expanded global licensing and collaboration agreements.

• Net profit was $64.9M, down from $73.0M in 2025, reflecting higher R&D and administrative expenses.

• Growth was fueled by molecule license & alliance revenue and deepened global partnerships.

• The company advanced multiple clinical and preclinical programs, expanded AI-driven R&D, and achieved significant clinical and business milestones, including IND approvals and strategic partnerships.

Financial highlights

• Revenue: $122.5M (up 20.9% YoY); profit: $64.9M (down $8.1M YoY).

• R&D costs: $29.6M (up from $18.0M YoY); administrative expenses: $16.7M (up from $7.4M YoY).

• Cash and cash equivalents: $359.2M as of 30 June 2026.

• Basic and diluted EPS: $0.08 (down from $0.09 YoY).

• Gross margin remained strong; cost of sales increased in line with revenue growth.

Outlook and guidance

• Continued focus on advancing mid-to-late stage clinical assets and expanding global partnerships, with key data readouts and regulatory milestones expected in the next 12–24 months.

• Ongoing investment in AI-driven R&D and technology platforms to accelerate innovation.